AT Bancorp reduced its position in Hologic, Inc. (NASDAQ:HOLX) by 37.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 69,032 shares of the medical equipment provider’s stock after selling 42,200 shares during the period. Hologic comprises about 0.4% of AT Bancorp’s investment portfolio, making the stock its 27th largest position. AT Bancorp’s holdings in Hologic were worth $3,132,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in HOLX. State Street Corp raised its stake in shares of Hologic by 1.5% in the first quarter. State Street Corp now owns 12,710,718 shares of the medical equipment provider’s stock worth $540,846,000 after buying an additional 189,572 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of Hologic by 418.5% in the first quarter. Victory Capital Management Inc. now owns 4,050,824 shares of the medical equipment provider’s stock worth $172,363,000 after buying an additional 3,269,503 shares in the last quarter. Bank of Montreal Can raised its stake in shares of Hologic by 6.6% in the second quarter. Bank of Montreal Can now owns 3,418,319 shares of the medical equipment provider’s stock worth $155,123,000 after buying an additional 211,550 shares in the last quarter. American Century Companies Inc. raised its stake in shares of Hologic by 229.4% in the first quarter. American Century Companies Inc. now owns 3,164,928 shares of the medical equipment provider’s stock worth $134,668,000 after buying an additional 2,204,085 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Hologic by 6.4% in the first quarter. Geode Capital Management LLC now owns 3,116,366 shares of the medical equipment provider’s stock worth $132,440,000 after buying an additional 186,854 shares in the last quarter. Institutional investors own 94.46% of the company’s stock.
Hologic, Inc. (HOLX) opened at 39.25 on Monday. The company has a market cap of $11.01 billion, a P/E ratio of 14.62 and a beta of 0.90. The company has a 50-day moving average of $45.06 and a 200 day moving average of $42.98. Hologic, Inc. has a one year low of $35.15 and a one year high of $46.80.
Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.01. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The firm had revenue of $806.10 million during the quarter, compared to analysts’ expectations of $799.70 million. During the same quarter last year, the company posted $0.51 earnings per share. The firm’s revenue was up 12.4% compared to the same quarter last year. Analysts anticipate that Hologic, Inc. will post $2.01 earnings per share for the current year.
A number of equities research analysts have weighed in on HOLX shares. Canaccord Genuity reiterated a “buy” rating and set a $53.00 target price on shares of Hologic in a research note on Tuesday, May 9th. Stifel Nicolaus boosted their target price on shares of Hologic from $45.00 to $48.00 and gave the company a “buy” rating in a research note on Thursday, May 11th. BTIG Research reiterated a “buy” rating and set a $47.00 target price on shares of Hologic in a research note on Sunday, May 14th. Zacks Investment Research lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Tuesday, May 23rd. Finally, Jefferies Group LLC set a $49.00 target price on shares of Hologic and gave the company a “buy” rating in a research note on Sunday, May 28th. Five analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $48.64.
In related news, Director Elaine Ullian sold 8,938 shares of the firm’s stock in a transaction on Friday, June 2nd. The shares were sold at an average price of $43.99, for a total transaction of $393,182.62. Following the sale, the director now owns 23,810 shares in the company, valued at $1,047,401.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Lawrence M. Levy sold 9,076 shares of the firm’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $42.80, for a total transaction of $388,452.80. Following the sale, the director now owns 43,165 shares in the company, valued at approximately $1,847,462. The disclosure for this sale can be found here. In the last three months, insiders have sold 63,562 shares of company stock valued at $2,802,013. 0.79% of the stock is currently owned by corporate insiders.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
